Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE · Real-Time Price · USD
8.17
-0.46 (-5.28%)
Mar 31, 2025, 10:45 AM EDT - Market open
Wave Life Sciences Revenue
In the year 2024, Wave Life Sciences had annual revenue of $108.30M, down -4.42%. Wave Life Sciences had revenue of $83.75M in the quarter ending December 31, 2024, with 188.23% growth.
Revenue (ttm)
$108.30M
Revenue Growth
-4.42%
P/S Ratio
11.01
Revenue / Employee
$376,049
Employees
288
Market Cap
1.25B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 108.30M | -5.00M | -4.42% |
Dec 31, 2023 | 113.31M | 109.66M | 3,005.10% |
Dec 31, 2022 | 3.65M | -37.32M | -91.09% |
Dec 31, 2021 | 40.96M | 20.89M | 104.03% |
Dec 31, 2020 | 20.08M | 4.09M | 25.61% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
WVE News
- 3 days ago - Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531 - Seeking Alpha
- 5 days ago - Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year - Benzinga
- 5 days ago - Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531 - GlobeNewsWire
- 26 days ago - Wave Life Sciences Ltd. (WVE) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 27 days ago - Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025 - GlobeNewsWire
- 7 weeks ago - Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity - GlobeNewsWire
- 2 months ago - Wave Life Sciences Is A Buy On Pipeline Prospects - Seeking Alpha